SCHEMBL6316246

SCHEMBL6316246

Nc1onc(-c2ccc(-c3cccc(Cl)c3)o2)c1C(=O)NCc1ccccc1Cl

nearest known ligand 0.47

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 2/20 0.43
ALDH1A1 P00352 2/20 0.43
POLB P06746 1/20 0.43
TP53 P04637 1/20 0.43
MAPT P10636 3/20 0.43
SMN1; SMN2 Q16637 1/20 0.42
ADORA3 P0DMS8 1/20 0.41
ADORA2A P29274 1/20 0.41
ADORA2B P29275 1/20 0.41
ADORA1 P30542 1/20 0.41
KMT2A Q03164 2/20 0.40
SCN2A Q99250 1/20 0.40
SCN10A Q9Y5Y9 1/20 0.40
NPC1 O15118 1/20 0.40
KDM4E B2RXH2 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6319272 0.91 RAB9A (0.42) RAB9AALDH1A1POLBTP53MAPT
SCHEMBL6324592 0.91 PRNP (0.45) RAB9AALDH1A1POLBTP53MAPT
SCHEMBL6316017 0.91 S1PR4 (0.45) RAB9AALDH1A1POLBTP53MAPT
SCHEMBL6323204 0.90 CHRNB2 (0.41) RAB9AALDH1A1POLBTP53MAPT
SCHEMBL6324284 0.88 TP53 (0.52) ALDH1A1TP53MAPTSMN1; SMN2ADORA3
SCHEMBL6316372 0.88 NTRK1 (0.44) RAB9AALDH1A1POLBMAPTNPC1
SCHEMBL6323058 0.88 NPC1 (0.51) RAB9AALDH1A1TP53MAPTADORA3
SCHEMBL6316611 0.87 RAB9A (0.48) RAB9AALDH1A1POLBTP53MAPT
SCHEMBL6321836 0.85 CA1 (0.53) RAB9AALDH1A1POLBTP53MAPT
SCHEMBL6323410 0.84 RAB9A (0.64) RAB9AALDH1A1POLBMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US claimed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP claimed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO claimed
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US disclosed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP disclosed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors MAP3K9, MAP3K19, MAP4K2 RAB9A 1754/4885ALDH1A1 4444/4885POLB 872/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.